5

10

15


the skin.

## Patent Claims

- 1. Use of cosmetic and dermatological formulations having
- a) a content of a compound or several compounds from the group consisting of flavonoids or having
- b) a content of an active compound combination comprising a compound or several compounds chosen from the group consisting of flavonoids in combination with a compound or several compounds chosen from the group consisting of cinnamic acid derivatives and
- c) if appropriate an additional content of a compound or several compounds from the group consisting of antioxidants for treatment or prophylactic treatment of the immunosuppression induced by UVB radiation, in particular for treatment or prophylactic treatment of inflammatory, allergic or autoimmune-reactive symptoms, and for protecting cells which participate in the immune response of
- 2. Use according to Claim 1, characterized in that
  the flavonoids are chosen from the group consisting of
  alpha-glucosylrutin, alpha-glucosylmyrictrin, alphaglucosylisoquercitrinin and alpha-glucosylquercitrin,
  quercitin, rutin, chrysin, kaempferol, myricetin, rhamnetin, apigenin, luteolin, naringin, hesperidin, naringenin, hesperitin, morin, phloridzin, diosmin, fisetin,
  vitexin, neohesperidin dihydrochalcone, flavone,
  glucosylrutin and genistein.
  - 3. Use according to Claim 1, characterized in that the formulations comprise combination b).
- 30 4. Use according to Claim 1, characterized in that the formulations comprise one or more hydroxycinnamic acids.
  - 5. Use according to Claim 1, characterized in that cinnamic acid derivatives of the formula

10

and/or active amounts of cinnamic acid derivatives of the general formula



wherein the groups X Y and R independently of one another can be chosen from the group consisting of H and branched or unbranched alkyl having 1-18 C atoms, are used.

- 6. Formulations according to Claim 1, characterized in that they comprise caffeic acid and/or ferulic acid.
- 7. Use according to Claim 1, characterized in that formulations with combinations b) comprise alpha-gluco-sylrutin and/or ferulic acid.

